Cara Therapeutics Inc (CARA)

[TheFinalCD]

yep...

[saigai]

ill take the crumbs...it just a game of chicken anymore...

[TheFinalCD]

whats very suspicious is that CARA was trading $29 before, then $15 in june, now with FDA Approval $14's

does that make any cents?


Jun 29 2021 14.43 -0.10 -0.69% 14.54 14.655 14.33 218,928
Jun 28 2021 14.53 -0.15 -1.02% 14.72 14.95 14.37 366,285
Jun 25 2021 14.68 0.17 1.17% 14.52 14.72 14.42 2,165,319
Jun 24 2021 14.51 0.53 3.79% 14.04 14.72 14.04 480,023
Jun 23 2021 13.98 0.09 0.65% 14.01 14.19 13.8563 825,516
Jun 22 2021 13.89 -0.45 -3.14% 14.43 14.43 13.80 657,343
Jun 21 2021 14.34 -0.21 -1.44% 14.58 14.58 14.05 489,001
Jun 18 2021 14.55 -0.10 -0.68% 14.36 14.58 14.01 1,016,569
Jun 17 2021 14.65 0.10 0.69% 14.72 $15.00 14.59 483,579
Jun 16 2021 14.55 0.37 2.61% 14.30 14.5899 14.15 877,519

https://ih.advfn.com/stock-market/NASDAQ/cara-therapeutics-CARA/historical/more-historical-data

https://www.tipranks.com/news/article/cara-therapeutics-could-climb-on-korsuva-drugs-success?utm_source=advfn.com&utm_medium=referral

[conix]

Stock needs to consolidate. I have moved over to a $2.00 Biotech stock that is coming off its bottom after consolidating. (IKT) But I will be back after CARA consolidates. Hopefully after booking a 50% gain soon.

[saigai]

yep..wont get to even today for me thats for sure

[TheFinalCD]

CARA CARA THERAPEUTICS 7,000 $15.03 +$0.75+$0.75 $105,210.00 -$3,368.34-3.1% $108,578.34 -$3,368.34 -3.1% $15.51

[TheFinalCD]

hit 15.28 was lookin betta, then back under 15


im going for a bike ride, Ive seen enough


news should carry this back up if they dont dilute or announce an offering

[conix]

Traders in control right now.

Scalpers profiting.

[saigai]

i agree.. very little good will here.. eventually rev speaks for now ..turd

[TheFinalCD]

CARA 14's


#TURD

[peterus]

will go red

[peterus]

lol

[Jake L]

CARA - MORNING REPORT

[TheFinalCD]

wow 15.20 yesterdays buyers $17-$19 getting taken to the woodshed

[saigai]

at the moment it is owned by the short side. so i will be here longer than i planned....OR.....

[saigai]

im in at 16.4 but it does not look good ..

[TheFinalCD]

filled 15.50 smh

CARA

[TheFinalCD]

16 what a joke

[Jake L]

CARA - Monday Rundown, Tuesday Expectations

[conix]

Chart on CARA

[a surfer]

Got the email about the FDA approval. Bout time! :) Always questioned the massive May drop.

[TheFinalCD]

https://www.caratherapeutics.com/our-pipeline/

[Jake L]

CARA - CARA Therapeutics FDA APPROVED

WALLSTREETBETS: 1k to 100k in 15 TRADES CARA Stock UPDATE $30pt

[crudeoil24]

Opps, lol. My mistake, that was in 2019. > I'm done with this stock.
Enjoy the evening!

[TheFinalCD]

TY

[crudeoil24]

Short interest is 7.22% of 40M trading float. CARA

[crudeoil24]

Closed shelf offering > that is positive catalyst:

Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock
STAMFORD, Conn., July 24, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the pricing of its underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $23.00 per share. The offering is expected to close on or about July 29, 2019, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Cara Therapeutics, are expected to be approximately $126.5 million. In addition, Cara Therapeutics expects to grant certain of the underwriters a 30-day option to purchase up to 825,000 additional shares of its common stock on the same terms and conditions. All of the shares in the proposed offering are to be sold by Cara Therapeutics.

[TheFinalCD]

18.30's niceeeee

[crudeoil24]

18.49

[conix]

After Hours--OVER $17

Patience paying off.

[crudeoil24]

Cara Therapeutics, Vifor Pharma Say FDA Approves Korsuva Injection
4:31 pm ET August 23, 2021 (Dow Jones) Print

By Stephen Nakrosis

Cara Therapeutics and Vifor Pharma on Monday said the U.S. Food and Drug Administration approved the Korsuva injection to treat pruritus in hemodialysis patients.

The companies said the Korsuva, or difelikefalin, injection was approved to treat moderate-to-severe pruritus in hemodialysis patients.

The companies said the Korsuva injection is the first and only therapy approved by the FDA to treat pruritus associated with chronic kidney disease in adult patients undergoing hemodialysis.

The companies said the promotional launch of Korsuva injection in the U.S. is expected in the first quarter of next year.


Write to Stephen Nakrosis at [e-mail]

[TheFinalCD]

7.13 to 7.75 in minutes

[TheFinalCD]

just dipped under $17 on NEWS

[PickleNick]

Big money soon…I think lol

[conix]

CARA chart

[Tower of Hanoi]

Did CARA do a split or just came off the rails?

[make it happen]

All Simple Moving Averages SMA's well below current PPS $16.99, $20.83 & $22.93. Weekly even lower in $16's. Should have a decent pull back imo

[make it happen]

Lots of gaps to fill for pull backs imo

Book Value Per Share $4.99

Cash Flow Statement
Operating Cash Flow (ttm) -5.49M
Levered Free Cash Flow (ttm) -9.67M

Revenue Per Share (ttm) $2.85

[a surfer]

CARA on the move!

[maddog27]

18 then 21 possible from here. Working in a triangle some work to get out. Bought 15.04 ... lows of this week plus a few 14.45 r stop, it goes or it doesn't

[whytestocks]

NEWS: $CARA Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva(TM)* to treat dialysis patients with pruritus

Vifor Pharma secures commercial rights for IV Korsuva in non- Fresenius Medical Care dialysis clinics representing approx. 66% of the market , under a profit - sharing arrangement with Cara Cara will receive a...

In case you are interested CARA - Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva(TM)* to treat dialysis patients with pruritus

[TFMG]

$CARA | #CaraTherapeutics Long into Earnings


Golden cross complete possible resistance at mid channel

[a surfer]

Getting frisky again.

[ClayTrader]

* * $CARA Video Chart 12-03-2019 * *

Link to Video - click here to watch the technical chart video

[TheFinalCD]

CARA down on P2 news

[BottomBounce]

$CARA was a Marijuana stock when it was hot. Short this turd

[a surfer]

Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology
Peptelligence® technology currently used in Oral KORSUVA™ formulation
STAMFORD, Conn., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has entered into a non-exclusive commercial license agreement with Enteris BioPharma, Inc. for oral formulation rights to Enteris’ Peptelligence® Technology.

“We are pleased to take another important step in advancing Oral KORSUVA™ as a potential novel treatment for chronic pruritus by entering into this commercial formulation license,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “With three ongoing Phase 2 trials across a range of patient populations for whom pruritus remains a significant unmet need, we are now well positioned to continue Oral KORSUVA’s development and potential future commercialization.”

Summary of the License Agreement

Under the terms of the License Agreement, Enteris granted Cara a non-exclusive license to its Peptelligence Technology to develop and commercialize Oral KORSUVA in any indication worldwide, excluding South Korea and Japan. Enteris will receive an upfront payment of $8 million, including $4 million in cash and $4 million in Cara common stock. Enteris is also eligible to receive development, regulatory and tiered commercial milestone payments, as well as low, single-digit royalties based on net sales in the licensed territory. Cara retains the right to buy out the royalty obligation for a period of two years under prespecified conditions.

About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets KORs located in the peripheral nervous system, and on immune cells. In a Phase 3 and two Phase 2 trials, KORSUVA (CR845/difelikefalin) Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in pruritus-related quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP), and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with chronic kidney disease, atopic dermatitis, and primary biliary cholangitis.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

[hogar]

Nice move by CARA- already above the offering price. Good sign when the share price quickly supersedes the $23/sh offering price.

[a surfer]

23 bucks a share is respectable for a raise. This won't get slammed down like before. 145 million Should be enough for 2 years easy.

[king oil]

Like clockwork. The share price starts to rally and they dilute the stock.